- Home
- CYBN vs LUCD Comparison
CYBN vs LUCD Comparison
Compare CYBN & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- LUCD
- Stock Information
- Founded
- CYBN 2019
- LUCD 2018
- Country
- CYBN Canada
- LUCD United States
- Employees
- CYBN N/A
- LUCD N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CYBN Health Care
- LUCD Health Care
- Exchange
- CYBN Nasdaq
- LUCD Nasdaq
- Market Cap
- CYBN 127.3M
- LUCD 135.6M
- IPO Year
- CYBN N/A
- LUCD 2021
- Fundamental
- Price
- CYBN $7.96
- LUCD $1.40
- Analyst Decision
- CYBN Strong Buy
- LUCD Strong Buy
- Analyst Count
- CYBN 4
- LUCD 4
- Target Price
- CYBN $86.00
- LUCD $3.88
- AVG Volume (30 Days)
- CYBN 326.6K
- LUCD 1.1M
- Earning Date
- CYBN 06-25-2025
- LUCD 05-14-2025
- Dividend Yield
- CYBN N/A
- LUCD N/A
- EPS Growth
- CYBN N/A
- LUCD N/A
- EPS
- CYBN N/A
- LUCD N/A
- Revenue
- CYBN N/A
- LUCD $4,173,000.00
- Revenue This Year
- CYBN N/A
- LUCD $98.50
- Revenue Next Year
- CYBN N/A
- LUCD $208.02
- P/E Ratio
- CYBN N/A
- LUCD N/A
- Revenue Growth
- CYBN N/A
- LUCD 39.89
- 52 Week Low
- CYBN $4.81
- LUCD $0.68
- 52 Week High
- CYBN $13.88
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- CYBN 61.23
- LUCD 58.18
- Support Level
- CYBN $7.00
- LUCD $1.21
- Resistance Level
- CYBN $8.50
- LUCD $1.70
- Average True Range (ATR)
- CYBN 0.53
- LUCD 0.11
- MACD
- CYBN 0.15
- LUCD 0.03
- Stochastic Oscillator
- CYBN 76.00
- LUCD 60.48
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.